(Circulation. 1999;99:2268-2275.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Amiodarone Interaction With ß-Blockers
Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases
From the Clinical Pharmacology Department, Claude Bernard University, Lyon, France (F.B., J.-P.B.); the Department of Medicine (S.C., J.A.C.) and Clinical Epidemiology and Biostatistics (M.G.), McMaster University, Hamilton, Ontario, Canada; the Department of Medicine, University of Toronto, Ontario, Canada (P.D.); Cardiological Sciences, St George's Hospital Medical School, London, UK (A.J.C.); Netherhall Gardens, London, UK (D.G.J.); the Department of Clinical and Experimental Cardiology, Academic Medical Centre, Amsterdam, Netherlands (M.J.J.); and Sanofi Recherche, Montpellier, France (G.F.).
Correspondence to Prof Jean-Pierre Boissel, Service de Pharmacologie Clinique, EA 643, 162 Avenue Lacassagne, BP 3041, 69394 Lyon Cédex 03, France. E-mail jpb{at}upcl.univ-lyon1.fr
Background—Investigations with in vitro and animal models suggest an interaction between amiodarone and ß-blockers. The objective of this work was to explore if an interaction with ß-blocker treatment plays a role in the decrease of cardiac arrhythmic deaths with amiodarone in patients recovered from an acute myocardial infarction.
Methods and Results—A pooled database from 2 similar randomized clinical trials, the European Amiodarone Myocardial Infarction Trial (EMIAT) and the Canadian Amiodarone Myocardial Infarction Trial (CAMIAT), was used. Four groups of post–myocardial infarction patients were defined: ß-blockers and amiodarone used, ß-blockers used alone, amiodarone used alone, and neither used. All analyses were done on an intention-to-treat basis. Unadjusted and adjusted relative risks for all-cause mortality, cardiac death, arrhythmic cardiac death, nonarrhythmic cardiac death, arrhythmic death, or resuscitated cardiac arrest were lower for patients receiving ß-blockers and amiodarone than for those without ß-blockers, with or without amiodarone. The interaction was statistically significant for cardiac death and arrhythmic death or resuscitated cardiac arrest (P=0.05 and 0.03, respectively). Findings were consistent across subgroups.
Conclusions—These findings are based on a post hoc analysis. However, they confirm prior results from in vitro and animal experiments suggesting an interaction between ß-blockers and amiodarone. In practice, not only is the adjunct of amiodarone to ß-blockers not hazardous, but ß-blocker therapy should be continued if possible in patients in whom amiodarone is indicated.
Key Words: antiarrhythmia agents • myocardial infarction • trials
This article has been cited by other articles:
 |
|
 |
|
  A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Den Ruijter, G. Berecki, T. Opthof, A. O. Verkerk, P. L. Zock, and R. Coronel Pro- and antiarrhythmic properties of a diet rich in fish oil Cardiovasc Res, January 15, 2007; 73(2): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1064 - 1108. [Full Text] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Zipes, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart J., September 1, 2006; 27(17): 2099 - 2140. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Schrickel, J. O. Schwab, A. Yang, H. Bielik, A. Bitzen, B. Luderitz, and T. Lewalter Pro-arrhythmic effects of amiodarone and concomitant rate-control medication Europace, June 1, 2006; 8(6): 403 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Connolly, P. Dorian, R. S. Roberts, M. Gent, S. Bailin, E. S. Fain, K. Thorpe, J. Champagne, M. Talajic, B. Coutu, et al. Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial JAMA, January 11, 2006; 295(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Singh {beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14. [Abstract] [PDF]
|
|
|
|
|
|
S. E. Shoaf, M. V. Elizari, Z. Wang, K. Sekar, L. R. Grinfeld, N. A. Barbagelata, J. Lerman, S. L. Bramer, J. Tronge, and C. Orlandi Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 165 - 171. [Abstract] [PDF]
|
|
|
|
|
|
K. Swedberg, L. G. Olsson, A. Charlesworth, J. Cleland, P. Hanrath, M. Komajda, M. Metra, C. Torp-Pedersen, and P. Poole-Wilson Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET Eur. Heart J., July 1, 2005; 26(13): 1303 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wachtell, B. Hornestam, M. Lehto, D. J. Slotwiner, E. Gerdts, M. H. Olsen, P. Aurup, B. Dahlof, H. Ibsen, S. Julius, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End point reduction in hypertension (LIFE) study J. Am. Coll. Cardiol., March 1, 2005; 45(5): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tachikawa, M. Kodama, K. Watanabe, T. Takahashi, M. Ma, T. Kashimura, M. Ito, S. Hirono, Y. Okura, K. Kato, et al. Amiodarone Improves Cardiac Sympathetic Nerve Function to Hold Norepinephrine in the Heart, Prevents Left Ventricular Remodeling, and Improves Cardiac Function in Rat Dilated Cardiomyopathy Circulation, February 22, 2005; 111(7): 894 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Josephson and H. J.J. Wellens Implantable Defibrillators and Sudden Cardiac Death Circulation, June 8, 2004; 109(22): 2685 - 2691. [Full Text] [PDF]
|
|
|
|
|
|
G. Fontaine and C. Prost-Squarcioni Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Cardiomyopathies Circulation, March 30, 2004; 109(12): 1445 - 1447. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, N. Freemantle, G. Kaye, M. Nasir, P. Velavan, K. Lalukota, T. Mudawi, R. Shelton, A. L. Clark, and A. P. Coletta Clinical trials update from the American Heart Association meeting: {Omega}-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE Eur J Heart Fail, January 1, 2004; 6(1): 109 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Reynolds and M. E. Josephson MADIT II (Second Multicenter Automated Defibrillator Implantation Trial) Debate: Risk Stratification, Costs, and Public Policy Circulation, October 14, 2003; 108(15): 1779 - 1783. [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh More on Amiodarone-Meeting the Challenges of the Combined Epidemics of Heart Failure and Atrial Fibrillation? Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 175 - 178. [PDF]
|
|
|
|
|
|
U. N. Srivatsa, R. Ebrahimi, A. El-Bialy, and R. Y. Wachsner Electrical Storm: Case Series and Review of Management Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 237 - 246. [Abstract] [PDF]
|
|
|
|
|
|
P. Dorian and I. Mangat Restoring sinus rhythm in atrial fibrillation: A pyrrhic victory? J. Am. Coll. Cardiol., July 2, 2003; 42(1): 30 - 32. [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, B. Bhambi, and T. Ishimori A better control for ICD patients? Eur. Heart J., December 2, 2002; 23(24): 1972 - 1972. [PDF]
|
|
|
|
|
|
B. N. Singh Antiarrhythmic Drugs in Cardiac Arrest Resuscitation: Intravenous Amiodarone or Intravenous Lidocaine? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2002; 7(2): 61 - 64. [PDF]
|
|
|
|
 |
|
 E Allot, C de Chillou, and N Sadoul Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D31 - D42. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Zaugg, M. C. Schaub, T. Pasch, and D. R. Spahn Modulation of {beta}-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action Br. J. Anaesth., January 1, 2002; 88(1): 101 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Huikuri, A. Castellanos, and R. J. Myerburg Sudden Death Due to Cardiac Arrhythmias N. Engl. J. Med., November 15, 2001; 345(20): 1473 - 1482. [Full Text] [PDF]
|
|
|
|
 |
|
 A V Ghuran and A J Camm Ischaemic heart disease presenting as arrhythmias Br. Med. Bull., October 1, 2001; 59(1): 193 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Coumel and A. A.M. Wilde Learning From Mistakes: The Case of Clinical Electrophysiology: A Perspective on Evidence-Based Rhythmology Circulation, August 14, 2001; 104(7): 845 - 847. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Wyse, M. Talajic, G. E. Hafley, A. E. Buxton, L. B. Mitchell, T. K. Kus, D. L. Packer, W. H. Kou, R. Lemery, P. Santucci, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis J. Am. Coll. Cardiol., August 1, 2001; 38(2): 344 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann, P. Lechat, P. Verkenne, and H. Wiemann Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure Eur J Heart Fail, August 1, 2001; 3(4): 469 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J Myerburg and P. M Spooner Opportunities for sudden death prevention: Directions for new clinical and basic research Cardiovasc Res, May 1, 2001; 50(2): 177 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Gollob and J. J. Seger Current Status of the Implantable Cardioverter-Defibrillator Chest, April 1, 2001; 119(4): 1210 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh and J. S. M. Sarma Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 69 - 87. [PDF]
|
|
|
|
 |
|
 D. M Roden ELECTROPHYSIOLOGY: Antiarrhythmic drugs: from mechanisms to clinical practice Heart, September 1, 2000; 84(3): 339 - 346. [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh Initial Antiarrhythmic Drug Therapy During Resuscitation from Sudden Cardiac Death: A Time for a Fundamental Change in Strategy? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 3 - 9. [PDF]
|
|
|
|
|
|
P. Dorian and D. Newman Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview Europace, January 1, 2000; 2(4): 277 - 285. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Connolly Evidence-Based Analysis of Amiodarone Efficacy and Safety Circulation, November 9, 1999; 100(19): 2025 - 2034. [Full Text] [PDF]
|
|
|
|
 |
|
 Use Beta-Blockers with Amiodarone If Possible Journal Watch Cardiology, July 9, 1999; 1999(709): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Beta-Blockers and Amiodarone Safe and Synergistic Journal Watch (General), May 18, 1999; 1999(518): 6 - 6. [Full Text]
|
|